Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15444607 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TDP1HSP90AA1MAPTKMT2A | |
| SCHEMBL15499903 | 0.85 | MAPT (0.42) | ALDH1A1TDP1HSP90AA1MAPTKMT2A | |
| SCHEMBL30865768 | 0.83 | CA1 (0.53) | ALDH1A1HSP90AA1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL875775 | 0.83 | F2 (0.45) | ALDH1A1HSP90AA1MAPTLMNAPOLB | |
| SCHEMBL24951911 | 0.82 | CA12 (0.45) | ALDH1A1MAPTKMT2ALMNAPOLB | |
| SCHEMBL27935675 | 0.81 | CA1 (0.47) | BCL9CTNNB1ALDH1A1HSP90AA1MAPT | |
| SCHEMBL15066367 | 0.80 | CA1 (0.44) | ALDH1A1HSP90AA1MAPTPOLBCA12 | |
| SCHEMBL27483143 | 0.80 | TSHR (0.53) | BCL9CTNNB1ALDH1A1TDP1LMNA | |
| SCHEMBL1759251 | 0.79 | CA1 (0.46) | ALDH1A1HSP90AA1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL10615596 | 0.79 | CA1 (0.48) | ALDH1A1HSP90AA1MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296681-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296681-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8604244-B2 | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012003501-A2 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | PNMT, TPH1, TPH2 | BCL9 2508/4885CTNNB1 4312/4885ALDH1A1 407/4885 |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | TPH1, TPH2, PNMT | BCL9 2750/4885CTNNB1 4226/4885ALDH1A1 610/4885 |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, TPH1, TPH2 | BCL9 2555/4885CTNNB1 4479/4885ALDH1A1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.